DENVER, June 13, 2016 /PRNewswire/ -- Remote
monitoring and automated coaching from ResMed (NYSE: RMD)
significantly improve the use of continuous positive airway
pressure therapy for patients with obstructive sleep apnea,
according to an independent Kaiser Permanente study presented last
night at the SLEEP conference in Denver – the largest-ever randomized,
controlled study on OSA in the United
States.
More than 500 patients on CPAP therapy received support,
including remote, automated coaching from ResMed's U-Sleep
platform, a secure, efficient solution clinicians use to manage
large groups of CPAP users "by exception" to quickly identify and
support patients who need help.
Patients who received support from U-Sleep achieved
Medicare-defined CPAP adherence 21 percent more than the average
study participant over a 90-day period, without additional provider
intervention.
"Anything that significantly increases CPAP use in the first 90
days is a big deal," said Dr. Dennis
Hwang, a sleep specialist at Kaiser Permanente's Fontana
Medical Center and the study's principal investigator. "That
initial period is crucial for patients to embrace CPAP to treat
their sleep apnea, which is linked to heart failure, atrial
fibrillation, type 2 diabetes and other serious conditions. Tools
like U-Sleep hold a lot of promise for patients on CPAP and the
clinicians who treat them."
"This study is further proof of the dramatic impact remote
monitoring, automated coaching and other digital health
technologies have on patients' health," said Raj Sodhi, ResMed's
president of healthcare informatics. "These results show great
promise for the role that remote monitoring and coaching can play
in helping treat a range of chronic diseases.
"ResMed is leading this space globally because of the pioneering
nature of our work, and the information we get from studies like
this one from Kaiser Permanente. We are improving people's lives
and advancing the practice of medicine through the work we're doing
to shape the frontier of digital health."
Well over 1 million CPAP users are connected every day to
ResMed's secure, cloud-enabled platforms, including U-Sleep, making
ResMed the world's #1 provider of connected healthcare solutions
for remote patient monitoring (Berg Insight 2015).
"What's equally impressive is that these results were achieved
with minimal provider intervention," said Sodhi. "This technology
directly addresses healthcare's 'triple aim' of better patient
care, improved population health and lower healthcare costs: a win
for patients, clinicians and other stakeholders in the healthcare
ecosystem."
Study details
This prospective, randomized, controlled
trial looked at patients referred to the Kaiser Permanente Fontana
Sleep Center for suspected OSA and evaluated the impact of two
telehealth mechanisms in 90-day compliance to CPAP therapy:
- OSA web-based educational program from Emmi Solutions, and
- Automated follow-up through ResMed's U-Sleep patient management
platform, which provided individualized feedback via text, email
and/or phone based on CPAP usage.
Of 1,455 randomized patients, 556 were prescribed AirSense™ 10
CPAP machines with built-in cellular communications: 129 were
placed into the usual care arm, 164 into the telehealth education
arm, 125 into telehealth CPAP monitoring through U-Sleep, and 138
into a combined telehealth education and CPAP monitoring arm.
The study found automated coaching through U-Sleep significantly
improved 3-month CPAP use (21 percent relative increase) without
additional provider intervention. Additionally, web-based education
on its own (one of four study arms) did not cause a statistically
significant impact on 3-month CPAP usage, though it did improve
attendance to initial clinic evaluations, strengthening the case
for technology intervention.
ResMed is showcasing its award-winning connected care devices
and sleep apnea adherence solutions at SLEEP in Denver, Booth #513, June 13–15, 2016.
About ResMed
ResMed (NYSE:RMD) changes lives with
award-winning medical devices and cutting-edge cloud-based software
applications that better diagnose, treat and manage sleep apnea,
chronic obstructive pulmonary disease (COPD) and other chronic
diseases. ResMed is a global leader in connected care, with more
than 1 million patients remotely monitored every day. Our
5,000-strong team is committed to creating the world's best
tech-driven medical device company – improving quality of life,
reducing the impact of chronic disease, and saving healthcare costs
in more than 100 countries.
ResMed.com | Facebook | Twitter | LinkedIn
For
Media:
|
For
Investors:
|
Alison Graves
|
Agnes Lee
|
Director, Global
Corporate Communications
|
Senior Director,
Investor Relations
|
Cell:
512.809.3339
|
Office:
858-836-5971
|
news@resmed.com
|
investorrelations@resmed.com
|
Logo -
http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/kaiser-permanente-study-resmed-digital-platform-drives-cpap-adherence-300283233.html
SOURCE ResMed Inc.